Pair Name	Sclareol, Doxorubicin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
	4T1	Malignant neoplasms of the mouse mammary gland	Mus musculus (Mouse)	CVCL_0125
Result	The developed SLN efficiently encapsulate DOX and SC and show good potential as an alternative for cancer treatment.

Pair Name	Sclareol, Doxorubicin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
	4T1	Malignant neoplasms of the mouse mammary gland	Mus musculus (Mouse)	CVCL_0125
In Vivo Model	4T1 (2.5×10⁶) tumour cells were subcutaneously injected into the right thigh of female BALB/c mice (5 weeks old, around 20 g).
Result	This work shows that SC and DOX present synergistic anticancer activity for breast cancer treatment whereas NLC-DOX-SC was a feasible alternative to attain the benefits posed by DOX:SC combination but with none to fewer side effects.